Antipsychotic polypharmacy in schizophrenia: benefits and risks. - Wikidata - wikimedia - TriplyDB

Antipsychotic polypharmacy in schizophrenia: benefits and risks.

Antipsychotic polypharmacy in schizophrenia: benefits and risks.

http://www.wikidata.org/entity/Q37863093

about

Antipsychotic dosing: found in translation Conformance to schizophrenia treatment guidelines in North West-Bank, Palestine: focus on antipsychotic dosing and polytherapy.Antipsychotic prescribing for vulnerable populations: a clinical audit at an acute Australian mental health unit at two-time points.Drug information update. Unconventional treatment strategies for schizophrenia: polypharmacy and heroic dosing.Adherence, healthcare resource utilization and Medicaid spending associated with once-monthly paliperidone palmitate versus oral atypical antipsychotic treatment among adults recently diagnosed with schizophrenia Implications and limitations of cellular reprogramming for psychiatric drug development.New roles for pharmacists in community mental health care: a narrative review.World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Schizophrenia, part 1: update 2012 on the acute treatment of schizophrenia and the management of treatment resistance.Factors associated with non evidence-based prescribing of antipsychotics Risperidone long-acting injection in Schizophrenia Spectrum Illnesses compared to first generation depot antipsychotics in an outpatient setting in Canada.Reducing the rates of prescribing high-dose antipsychotics and polypharmacy on psychiatric inpatient and intensive care units: results of a 6-year quality improvement programme.Evaluation of the individual safe correction of antipsychotic agent polypharmacy in Japanese patients with chronic schizophrenia: validation of safe corrections for antipsychotic polypharmacy and the high-dose method.The impact of antipsychotic polytherapy costs in the public health care in Sao Paulo, Brazil Effect of pharmacist intervention on physician prescribing in patients with chronic schizophrenia: a descriptive pre/post study.Antipsychotic monotherapy among outpatients with schizophrenia treated with olanzapine or risperidone in Japan: a health care database analysis Implementation of a clinical practice guideline for schizophrenia in a specialist mental health center: an observational study A retrospective study of clinical usage of quetiapine XR and quetiapine IR in outpatients with schizophrenia in Denmark.Use of quetiapine XR and quetiapine IR in clinical practice for hospitalized patients with schizophrenia: a retrospective study.Economic burden associated with extrapyramidal symptoms in a medicaid population with schizophrenia.Do doctors agree on doses of antipsychotic medications?Is rational antipsychotic polytherapy feasible? A selective review.Pharmacogenetics: a reality or misplaced optimism?A retrospective study of psychotropic drug use among individuals with mental illness issued a community treatment order.Treating the violent patient with psychosis or impulsivity utilizing antipsychotic polypharmacy and high-dose monotherapy."First do no harm." A systematic review of the prevalence and management of antipsychotic adverse effects.QTc interval in patients with schizophrenia receiving antipsychotic treatment as monotherapy or polypharmacy.Current psychotropic medication prescribing patterns in late-life bipolar disorder.What leads to high antipsychotic dosing in forensic patients with schizophrenia?Trends in antipsychotic prescriptions for Japanese outpatients during 2006-2012: a descriptive epidemiological study.Immediate vs Gradual Discontinuation in Antipsychotic Switching: A Systematic Review and Meta-analysis.Functioning in patients with schizophrenia: a systematic review of the literature using the International Classification of Functioning, Disability and Health (ICF) as a reference.Clozapine treatment and discontinuation in Iceland: A national longitudinal study using electronic patient records.Predictors of antipsychotic monotherapy with olanzapine during a 1-year naturalistic study of schizophrenia patients in Japan.Psychopharmacological treatment for schizophrenia: less is more.Comparison of patients undergoing switching versus augmentation of antipsychotic medications during treatment for schizophrenia.Atypical antipsychotics usage in long-term follow-up of first episode schizophrenia.Blonanserin Augmentation of Atypical Antipsychotics in Patients with Schizophrenia-Who Benefits from Blonanserin Augmentation?: An Open-Label, Prospective, Multicenter Study.Antipsychotic Use Pattern in Schizophrenia Outpatients: Correlates of Polypharmacy.Network-assisted investigation of antipsychotic drugs and their targets.Medication discontinuation with depot and oral antipsychotics in outpatients with schizophrenia: comparison of matched cohorts from a 12-month observational study.

P2860

Q26863343-F7208B8E-D688-4636-97B8-E1E505779C09 Q33455799-1AEE15BF-59DC-4FAB-BAF9-066017A164C9 Q33560808-B480035B-0328-46E4-9B85-F7DAC4D7A7F5 Q33747710-63AC19EE-0705-4330-973F-6550687D66B9 Q33759300-B774099D-A78B-417B-B4C4-351646845375 Q34385134-C9558663-CF99-4179-8506-99D5063BAED1 Q34412191-3FB01E98-691B-4D57-8ECF-A8012F2882C6 Q34640811-AD40F4EA-15B2-4263-A513-3DA676703A6E Q34642808-034B9ED8-D0E7-4567-BF85-E1399230585E Q34746791-D3ECD98E-52CF-46C3-8110-2C3B9CDCD45F Q35044176-2487E7A5-5B33-48F3-8B31-34EC33FFFB2D Q35224262-5E276C8A-BAFD-465E-9A71-2527FD62EADC Q35324015-E9D0F099-0929-4256-ABA8-C24C5B390D88 Q36000102-D186575D-AC2D-49A4-A65A-FE85F4316527 Q36065092-AF42398D-757F-4036-8884-AF3C42F214BB Q36101841-F52E44E7-1E9C-4E6D-96E6-860C2F8EB86A Q36387635-A9168011-C095-420B-8CA0-650709EA7B7A Q37079066-5AF7A4BF-CA3D-409C-BBD7-62084AC424CB Q37492362-1670F15C-B574-47AE-8418-0C8869E4F285 Q37514630-A5CAF3A8-5BBB-43D9-BBA2-1A5709D9F11A Q37993473-497F0378-4EFF-49B3-B853-6D73FB4C3818 Q38003392-DC3EC2A2-4178-4F8E-81ED-D84430842DAF Q38174188-1B29C750-EE1A-4841-8BDC-6973388718D8 Q38239613-225AD6A4-322A-4FEE-9103-F2DC199B8184 Q38291338-0B1BA71E-D353-4BCB-A959-E275E910CF61 Q38704005-C7F4527D-D416-4C73-8F2F-5BFEB0765E20 Q38788092-1C4CB6A7-2FE5-41EF-8E1E-803B781A0B5A Q38831644-65028D5C-05CB-4C01-8804-98B438BB85B1 Q38925657-735A05D7-AC9B-4ABB-821A-88C2545E7B87 Q39043789-AF5FCB7E-3BB7-4CD8-AA3A-E99B3124207D Q39057150-2858C452-6A65-4E30-80F9-B3332E3087DA Q40815632-909A7A4C-36C2-4AE9-AEF7-EBFA3BDAE75C Q41064310-9908F7DA-19A2-4862-B32F-872F23D63EBF Q41078277-1765FEBD-2E98-48BE-8FC2-A34A4868E562 Q42131509-D7666C69-FFAA-4E9E-8B85-2AF26B778D4A Q42380356-C0DE4178-2C05-43B6-BF20-F8074952E9A1 Q42395373-6A20931A-0232-43FB-8BF8-7EFA35F898B9 Q42707831-A5622A7F-04DF-4318-9BCD-FF24892FCA46 Q43836810-BAF0C406-03CD-4EA7-9BFB-5C3EED09B2BC Q44733793-E1445791-FE73-461A-AD53-C173112633D1

P2860

Antipsychotic polypharmacy in schizophrenia: benefits and risks.

http://www.wikidata.org/entity/Q37863093

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on May 2011

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Antipsychotic polypharmacy in schizophrenia: benefits and risks.

@en

Antipsychotic polypharmacy in schizophrenia: benefits and risks.

@nl

type

label

Antipsychotic polypharmacy in schizophrenia: benefits and risks.

@en

Antipsychotic polypharmacy in schizophrenia: benefits and risks.

@nl

prefLabel

Antipsychotic polypharmacy in schizophrenia: benefits and risks.

@en

Antipsychotic polypharmacy in schizophrenia: benefits and risks.

@nl

P1433

Q37863093-B251AB1D-6799-480D-BF5A-EF5E9C02BDBB

P1476

Q37863093-2B78B4CE-A047-4DE1-BDC3-52A5891E7DDC

P2093

Q37863093-29FF9D56-EA29-4CB3-9A5E-A3D07780DC00

Q37863093-B43862DA-58EB-47EE-8ED6-AF75AFECC969

P2860

Q37863093-06343909-7245-468E-BFC5-AA9A8D22B0BF

Q37863093-14653ACB-2158-42B8-A55A-3AF6D165C17E

Q37863093-16E68CCA-8409-4746-9644-66201F9A1C28

Q37863093-18B45119-EB64-4DAD-A8D0-773F22546A5E

Q37863093-196BF4AE-5D5B-4AD2-87E4-692505ED0FB6

Q37863093-1C4926A6-372C-45D6-A9D8-EAB9F20FF2B0

Q37863093-2053F76E-7568-43DF-82F2-477D7E5165CC

Q37863093-20789E55-7076-4A14-AB61-11CE9C28A629

Q37863093-214376CA-A603-410A-A97A-CAAEE4DBF08F

Q37863093-232504DE-00A3-4534-994C-BD8D327DEEA2

P2888

Q37863093-E4E74C05-C1B5-4A26-B60F-43845277AFA5

P304

Q37863093-015B6CD3-3C1C-46FC-A7AF-F1C8D843F6A9

P31

Q37863093-58E2EB31-F103-4BD9-B2FD-126E0A3115D4

P356

Q37863093-3CEED8D7-FF26-4872-90FB-6B74B3547FD6

P433

Q37863093-3B1AF17E-466A-4938-BE83-64E718E1E23B

P478

Q37863093-7DAB0519-0857-41D6-95D0-6E6CDFDB59EF

P577

Q37863093-B619F725-42D7-47AD-BE47-57E9C0E146CA

P698

Q37863093-405FF325-9545-4133-9520-E52E1472CF7C

P921

Q37863093-11BCEFDD-24AC-42DB-90DB-1B5969F4775E

P356

11587810-000000000-00000

P1433

P1476

Antipsychotic polypharmacy in schizophrenia: benefits and risks.

@en

P2093

Carol Paton

http://www.w3.org/2001/XMLSchema#string

Thomas R E Barnes

http://www.w3.org/2001/XMLSchema#string

P2860

Closing the gap between research and practice: an overview of systematic reviews of interventions to promote the implementation of research findings. The Cochrane Effective Practice and Organization of Care Review Group.

Antipsychotic monotherapy and polypharmacy in the naturalistic treatment of schizophrenia with atypical antipsychotics

Determinants of medication compliance in schizophrenia: empirical and clinical findings

Amisulpride augmentation in patients with schizophrenia partially responsive or unresponsive to clozapine. A randomized, double-blind, placebo-controlled trial

Implementing evidence-based practices for people with schizophrenia

Comparison of antipsychotic medication effects on reducing violence in people with schizophrenia

The 2009 schizophrenia PORT psychopharmacological treatment recommendations and summary statements

Use of antipsychosis and adjunctive medications by an inner urban community psychiatric service.

Influence of antipsychotics on mortality in schizophrenia: systematic review.

Antipsychotic dosing patterns for schizophrenia in three treatment settings.

P2888

11587810-000000000-00000

P304

383-399

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.2165/11587810-000000000-00000

http://www.w3.org/2001/XMLSchema#string

P433

5

http://www.w3.org/2001/XMLSchema#string

P478

25

http://www.w3.org/2001/XMLSchema#string

P577

2011-05-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

21476610

http://www.w3.org/2001/XMLSchema#string

P921